Serum c-erbB-2 levels in monitoring of operable breast cancer patients

Japanese Journal of Clinical Oncology

Volumn 29, Issue 7, 1999, Pages 336-339

  Imoto, Shigeru ^a   Kitoh, Takashi ^b   Hasebe, Takahiro ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Nichirei Corporation   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Breast cancer; c erbB 2; Enzyme immunoassay; Sera; Tumor marker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; BLOOD; BREAST TUMOR; FEMALE; HUMAN; MONITORING;

BREAST NEOPLASMS; FEMALE; HUMANS; MONITORING, PHYSIOLOGIC; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0033160432     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.7.336     Document Type: Article

References (28)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, et al. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 1990;81:489-94.
3. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
4. Borg Å, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SAW, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-7.
5. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-42.
6. Hartmann LC, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, et al. Prognostic value of c-erbB-2 overexpression in axillary lymph node positive breast cancer. Cancer 1994;74:2956-63.
7. Piffanelli A, Dittadi R, Catozzi L, Gion M, Capitanio G, Brazzale A, et al. Determination of erbB-2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. Breast Cancer Res Treat 1996;37:267-76.
8. ASCO Tumor Marker Expert Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
9. Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S, et al. ErbB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137-44.
10. Stål O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, et al. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31A:2185-90.
11. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
12. Sugano K, Kawai T, Ishii M, Koyama H, Kitajima M, Kasumi F, et al. Clinical evaluation of serum erbB-2 protein using enzyme immunoassay. Gan To Kagakuryoho 1994;21:1255-62 (in Japanese).
13. Sugano K, Kitajima M, Ishii M, Koyama H, Kasumi F, Demura R, et al. Clinical evaluation of erbB-2 protein in tissue extract using an enzyme immuno assay (erbB-2 EIA 'NICHIREI'). Gan To Kagakuryoho 1994; 21:1957-66 (in Japanese).
14. Imoto S, Ohkura H, Sugano K, Sasaki Y, Ito K, Igarashi T, et al. Determination of cytosol c-erbB-2 protein in breast cancer by sandwich enzyme immunoassay. Jpn J Clin Oncol 1998;28:92-6.
15. Masuko T, Sugahara K, Kozono M, Otsuki S, Akiyama T, Yamamoto T, et al. A murine monoclonal antibody that recognizes as extracellular domain of the human c-erbB-2 protooncogene product. Jpn J Cancer Res 1989;80:10-4.
16. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 1989;65:1794-1800.
17. Narita T, Funahashi H, Satoh Y, Takagi H. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992;24:97-102.
18. Isola JJ, Holli K, Oksa H, Teramoto Y, Kallioniemi O-P. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994;73:652-8.
19. Fontana X, Ferrari P, Namer M, Peysson R, Salanon C, Bussiere F. C-erbB-2 gene amplification and serum levels of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res 1994;14:2099-104.
20. Kandl H, Bezwoda SWR. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994;70:739-42.
21. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Børresen AL. Detection of c-erbB-2 related protein in sera from breast cancer patients. Acta Oncol 1995;34:499-504.
22. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis EO, Blamey RW, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996;40:251-5.
23. Molina R, Jo J, Zanón G, Filella X, Farrus B, Muñoz M, et al. Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic anticen and CA15.3. Br J Cancer 1996;74:1126-31.
24. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7.
25. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35.
26. Revillion F, Hebbar M, Bonneterre J, Peyrat JP. Plasma c-erbB-2 concentrations in relation to chemotherapy in breast cancer patients. Eur J Cancer 1996;32A:231-4.
27. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DT, Hösch S, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-25.
28. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jäger W, et al. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:87-95.